
PPC 8: PERFORMANCE REPORTING AND IMPROVEMENT

Element D: Setting Goals and Taking Action


Item 1: Set goals based on measurement results in Elements A and B

CHC-A's strategic plan set goals several key areas across the organization.




For diabetes, we have set goals based on the Health Disparities Network and NCQA measures.


Diabetes Registry Measures/Goals:	Average A1c < 8%	90% of patients have two A1cs in	40% of patients with last BP < 130/80	<12% of patients	90% of patients have an annual foot exam	70% of patients have an annual
	40% of patients have A1cs < 7%	the last 12 months	70% of patients with last LDL < 100	are current smokers	90% of patients have an annual eye exam	self-management goal documented



Our value added time measure is set at 60%, which is based on a time study performed by XXXXX Foundation for Medical Care for Medicare's DOQ-IT program.





Time to third goal is to have same day access.





Item 2: Take action where identified to improve performance

For our diabetes population, we worked with Providers at the Pod level using the PDSA model to improve outcomes. Provider received their data on a monthly basis. We created Provider champions on each Pod who would then help the other Providers on their team with their diabetes outcomes. All our PDSAs are stored in a PDSA database for institutional memory and spread. Below is a screen shot of the PDSA with our diabetes population, outcome measures and a screen shot of our diabetes flowsheet in the EMR.













Our EMR has a flowsheet and decision support built in for our planned care conditions.







We are also working with the University of Xxxx School of Pharmacy on a Service for Anticoagulation Management Safety Project. Our Aim is to improve the care provided to patients taking Warfarin for anticoagulation therapy. We want to increase the number of patients seen at appropriate intervals; increase the number of patients who's last INR was in range and prevent complications from under or over anticoagulation. We also want to increase our patient's activation in managing their disease and medication.







Participation in the National Safety Collaboration requires a spread strategy. Our plan is to extend pharmacy services for medication therapy management from the existing population of focus to the 41 to the 142 patients on Warfarin in our organization during the two year collaborative ending September 2011.



Our EMR has a flowsheet and decision support built in for our planned care conditions.

Referring Physician		Ful	I TI-C I Name n Test	OAG	ULA	TIOI	Date o		Phone:	Alternate Pho
Indications For Therapy						Expe	apy star ected du ligh Risk	ration of therapy:	stopped:	11
Week One (?) Target Range: .00 to .00 Lab Date INR Protime // Additional Dosage	Tablet Sun		ge dose 3m Tue 3mg 0.5	g C vVed 3mg 0.5	Thu 3mg 0.5	C Cle Fri 3mg	ear Sat 3mg	Weekly	Dosage 1.50mg 3.00mg	? Su,Tu,W,Th/ M,F,Sa
Comments Totals Week Two ?	1.50	3.00 Chang	1.50 ge dose	1.50	1.50	3.00	3.00			
Target Range: .00 to .00 Lab Date INR Protime / / Additional Dosage	Sun			(Ved	Thu	C Cle	ar Sat	vVeekly	Dosage	
Comments Totals	.00	.00	.00	.00	.00	.00	.00			Page Do
										Page U